Sfoglia per Autore
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions
2013 Galante, A; Bonechi, E; Mariottini, A; Aldinucci, A; Biagioli, T; Mechi, C; Repice, A; Massacesi, L; Ballerini, C
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis
2015 Mariottini, A; Innocenti, C; Repice, AM; Fani, A; Massacesi, L; Saccardi, R
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis
2016 Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports
2016 Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience
2016 Saccardi, R; Repice, AM; Innocenti, C; Mariottini, A; Amato, MP; Guidi, S; Fani, A; Nistri, R; Giannini, M; Portaccio, E; Barilaro, A; Nozzoli, C; Gozzini, A; Massacesi, L
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience
2016 Saccardi, R; Barilaro, A; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Innocenti, C; Mariottini, A; Nozzoli, C; Portaccio, E; Repice, AM; Amato, MP; Massacesi, L
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience
2017 Boffa, G; Sormani, MP; Repice, AM; Curro, D; Capobianco, M; Gualandi, F; Lo Re, M; De Gobbi, M; Innocenti, C; Capello, E; Mariottini, A; Forci, B; Uccelli, A; Barilaro, A; Cottone, S; Bertolotto, A; Saccardi, R; Mancardi, GL; Massacesi, L
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports
2017 Mariottini, A; Forci, B; Magnani, E; Massacesi, L; Repice, A
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments
2017 Forci, B; Mariottini, A; Mechi, C; Magnani, E; Barilaro, A; Massacesi, L; Repice, A
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
2017 Forci, B; Mariottini, A; Mechi, C; Massacesi, L; Repice, A.
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg
2018 Aldinucci, A; Rizzo, R; Bonechi, E; Fainardi, E; Bortolotti, D; Mariottini, A; Mechi, C; Repice, AM; Massacesi, L; Ballerini, C
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis
2018 Innocenti, C; Amato, MP; Barilaro, A; Bianchini, G; Capobianco, T; Calia, MA; Ceschini, R; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Rossolini, G; Saccardi, R
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study
2019 Pasca, M; Forci, B; Mechi, C; Mariottini, A; Barilaro, A; Massacesi, L; Repice, AM
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis
2019 Mariottini, A; Filippini, S; Di Tullio, MG; Forci, B; Innocenti, C; Barilaro, A; Fani, A; Saccardi, R; Massacesi, L; Repice, AM
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments
2019 Forci, B; Mariottini, A; Mechi, C; Magnani, E; Barilaro, A; Falcini, M; Palumbo, P; Massacesi, L; Repice, AM
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation
2019 Mechi, C; Mariottini, A; Pasca, M; Forci, B; Magnani, E; Barilaro, A; Repice, AM; Massacesi, L
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis.
2019 Mariottini A, Innocenti C, Forci B, Magnani E, Mechi C, Barilaro A, Nistri R, Fani A, Saccardi R, Massacesi L, Repice AM.
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen
2019 Innocenti, C; Di Gioia, M; Amato, MP; Ciccone, N; Cutini, I; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Maria, RG; Saccardi, R
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials
2020 Signori A.; Boffa G.; Bovis F.; Mariottini A.; Repice A.; Inglese M.; Amato M.P.; Mancardi G.; Massacesi L.; Saccardi R.; Sormani M.P.
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status
2020 Mariottini, Alice; De Matteis, Eleonora; Muraro, Paolo A.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions | 2013 | Galante, A; Bonechi, E; Mariottini, A; Aldinucci, A; Biagioli, T; Mechi, C; Repice, A; Massacesi, L; Ballerini, C | |
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis | 2015 | Mariottini, A; Innocenti, C; Repice, AM; Fani, A; Massacesi, L; Saccardi, R | |
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis | 2016 | Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R | |
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports | 2016 | Innocenti, C; Barilaro, A; Fani, A; Mariottini, A; Massacesi, L; Repice, AM; Saccardi, R | |
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience | 2016 | Saccardi, R; Repice, AM; Innocenti, C; Mariottini, A; Amato, MP; Guidi, S; Fani, A; Nistri, R; Giannini, M; Portaccio, E; Barilaro, A; Nozzoli, C; Gozzini, A; Massacesi, L | |
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience | 2016 | Saccardi, R; Barilaro, A; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Innocenti, C; Mariottini, A; Nozzoli, C; Portaccio, E; Repice, AM; Amato, MP; Massacesi, L | |
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience | 2017 | Boffa, G; Sormani, MP; Repice, AM; Curro, D; Capobianco, M; Gualandi, F; Lo Re, M; De Gobbi, M; Innocenti, C; Capello, E; Mariottini, A; Forci, B; Uccelli, A; Barilaro, A; Cottone, S; Bertolotto, A; Saccardi, R; Mancardi, GL; Massacesi, L | |
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports | 2017 | Mariottini, A; Forci, B; Magnani, E; Massacesi, L; Repice, A | |
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments | 2017 | Forci, B; Mariottini, A; Mechi, C; Magnani, E; Barilaro, A; Massacesi, L; Repice, A | |
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. | 2017 | Forci, B; Mariottini, A; Mechi, C; Massacesi, L; Repice, A. | |
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg | 2018 | Aldinucci, A; Rizzo, R; Bonechi, E; Fainardi, E; Bortolotti, D; Mariottini, A; Mechi, C; Repice, AM; Massacesi, L; Ballerini, C | |
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis | 2018 | Innocenti, C; Amato, MP; Barilaro, A; Bianchini, G; Capobianco, T; Calia, MA; Ceschini, R; Fani, A; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Rossolini, G; Saccardi, R | |
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study | 2019 | Pasca, M; Forci, B; Mechi, C; Mariottini, A; Barilaro, A; Massacesi, L; Repice, AM | |
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis | 2019 | Mariottini, A; Filippini, S; Di Tullio, MG; Forci, B; Innocenti, C; Barilaro, A; Fani, A; Saccardi, R; Massacesi, L; Repice, AM | |
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments | 2019 | Forci, B; Mariottini, A; Mechi, C; Magnani, E; Barilaro, A; Falcini, M; Palumbo, P; Massacesi, L; Repice, AM | |
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation | 2019 | Mechi, C; Mariottini, A; Pasca, M; Forci, B; Magnani, E; Barilaro, A; Repice, AM; Massacesi, L | |
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis. | 2019 | Mariottini A, Innocenti C, Forci B, Magnani E, Mechi C, Barilaro A, Nistri R, Fani A, Saccardi R, Massacesi L, Repice AM. | |
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen | 2019 | Innocenti, C; Di Gioia, M; Amato, MP; Ciccone, N; Cutini, I; Giannini, M; Gozzini, A; Guidi, S; Mariottini, A; Massacesi, L; Nozzoli, C; Repice, A; Maria, RG; Saccardi, R | |
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials | 2020 | Signori A.; Boffa G.; Bovis F.; Mariottini A.; Repice A.; Inglese M.; Amato M.P.; Mancardi G.; Massacesi L.; Saccardi R.; Sormani M.P. | |
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status | 2020 | Mariottini, Alice; De Matteis, Eleonora; Muraro, Paolo A. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile